![](https://ml.globenewswire.com/media/3637f1b5-adfe-4a2c-8fbe-c3cd34cdd7b1/small/celz-logo-2024-png.png)
Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program
PHOENIX, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced promising one-year follow-up data from the AlloStem ™ ( …